RESEARCH TRIANGLE PARK, N.C. – For the second year in a row, Quintiles has been named the CRO industry leader in Phase I services, according to respondents in Industry Standard Research’s (ISR) report, CRO Quality Benchmarking Phase I Service Providers (2014).

In this year’s survey, Quintiles was recognized as the “overwhelming leader” when survey respondents were asked to identify Contract Research Organizations (CROs) they consider leaders in the Phase I space.

This announcement follows Quintiles’ recognition as the industry leader that best differentiates itself on service quality for Phase II/III research in an earlier ISR report released in April.

In this new report, Quintiles was mentioned by 60 percent of the 113 decision-makers who were surveyed around the globe as the industry-leading service provider. In addition to leading all large CROs in service provider loyalty – a compilation of overall satisfaction, willingness to recommend and likelihood to use again – Quintiles also was identified as the service provider that respondents from small and mid-sized pharmaceutical companies prefer to work with out of all CROs.

“I am delighted to see that Quintiles once again is the leader by a wide margin among Phase I service providers,” said Dr. Oren Cohen, senior vice president of Early Clinical Development at Quintiles.

Survey respondents also identified Quintiles as the “best service provider for differentiation” based on service quality, with particular strengths in therapeutic expertise, scientific knowledge, data quality, financial strength/stability, and local market/regulatory knowledge.

Quintiles is one of the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 29,000 employees conducting business in approximately 100 countries.